Income Statement

v3.19.3
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
REVENUES        
Real property rental $ 264,141 $ 272,444 $ 795,656 $ 847,939
Medical related consulting services - related parties 108,520 71,398 234,214 213,394
Development services and sales of developed products 10,555 69,661 37,237 156,176
Total Revenues 383,216 413,503 1,067,107 1,217,509
COSTS AND EXPENSES        
Real property operating expenses 193,738 190,899 617,173 597,114
Medical related consulting services - related parties 94,442 64,196 202,908 188,911
Development services and sales of developed products 41,808 40,386 103,899 98,999
Total Costs and Expenses 329,988 295,481 923,980 885,024
REAL PROPERTY OPERATING INCOME 70,403 81,545 178,483 250,825
GROSS PROFIT FROM MEDICAL RELATED CONSULTING SERVICES 14,078 7,202 31,306 24,483
GROSS (LOSS) PROFIT FROM DEVELOPMENT SERVICES AND SALES OF DEVELOPED PRODUCTS (31,253) 29,275 (66,662) 57,177
OTHER OPERATING EXPENSES:        
Compensation and related benefits 2,187,959 569,915 6,388,292 1,596,181
Research and development expenses 265,139 1,384 1,367,310 1,647
Other general and administrative 2,066,466 1,926,141 5,662,926 3,642,048
Impairment loss 1,010,011 1,010,011
Total Other Operating Expenses 5,529,575 2,497,440 14,428,539 5,239,876
LOSS FROM OPERATIONS (5,476,347) (2,379,418) (14,285,412) (4,907,391)
OTHER INCOME (EXPENSE)        
Interest expense (2,356) (25,205) (36,875) (287,123)
Interest expense - related party (8,842) (23,425)
Change in fair value of warrants liabilities 1,160,137 1,621,630
Financing expense (525,418)
Loss from equity-method investment (25,266) (48,353)
Foreign currency transaction gain (loss) 16,125 16,125 (106,929)
Other income 2,491 1,372 3,918 3,408
Total Other Income (Expense), net 1,142,289 (23,833) 1,007,602 (390,644)
LOSS BEFORE INCOME TAXES (4,334,058) (2,403,251) (13,277,810) (5,298,035)
INCOME TAXES
NET LOSS (4,334,058) (2,403,251) (13,277,810) (5,298,035)
LESS: NET LOSS ATTRIBUTABLE TO NON-CONTROLLING INTEREST (475,863) (58,581) (656,575) (177,392)
NET LOSS ATTRIBUTABLE TO AVALON GLOBOCARE CORP. COMMON SHAREHOLDERS (3,858,195) (2,344,670) (12,621,235) (5,120,643)
COMPREHENSIVE LOSS:        
NET LOSS (4,334,058) (2,403,251) (13,277,810) (5,298,035)
OTHER COMPREHENSIVE LOSS        
Unrealized foreign currency translation loss (69,388) (94,069) (60,009) (137,438)
COMPREHENSIVE LOSS (4,403,446) (2,497,320) (13,337,819) (5,435,473)
LESS: COMPREHENSIVE LOSS ATTRIBUTABLE TO NON-CONTROLLING INTEREST (471,411) (58,794) (651,421) (177,564)
COMPREHENSIVE LOSS ATTRIBUTABLE TO AVALON GLOBOCARE CORP. COMMON SHAREHOLDERS $ (3,932,035) $ (2,438,526) $ (12,686,398) $ (5,257,909)
NET LOSS PER COMMON SHARE ATTRIBUTABLE TO AVALON GLOBOCARE CORP. COMMON SHAREHOLDERS:        
Basic and diluted $ (0.05) $ (0.03) $ (0.17) $ (0.07)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:        
Basic and diluted 75,665,676 72,573,462 74,859,871 71,611,375

Source